GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple myeloma from Chinese biotechnology company Chimagen Biosciences in a deal worth up to $750 million, as ...

GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid tumours. Under the licensing deal, a subsidiary of GSK will gain global rights to the ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...